Repositioning Candidate Details
| Candidate ID: | R0606 |
| Source ID: | DB04552 |
| Source Type: | experimental |
| Compound Type: | small molecule |
| Compound Name: | Niflumic acid |
| Synonyms: | NFA; Niflumic acid |
| Molecular Formula: | C13H9F3N2O2 |
| SMILES: | OC(=O)C1=C(NC2=CC=CC(=C2)C(F)(F)F)N=CC=C1 |
| Structure: |
|
| DrugBank Description: | Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. |
| CAS Number: | 4394-00-7 |
| Molecular Weight: | 282.218 |
| DrugBank Indication: | Used in the treatment of rheumatoid arthritis. |
| DrugBank Pharmacology: | Niflumic acid, a nonsteroidal anti-inflammatory fenamate, is a Ca<sup>2+</sup>-activated Cl<sup>-</sup> channel blocker. |
| DrugBank MoA: | Niflumic acid is able to inhibit both phospholipase A2 as well as COX-2, thereby acting as an antiinflamatory and pain reduction agent. |
| Targets: | Phospholipase A2 inhibitor; Prostaglandin G/H synthase 2 inhibitor; Chloride channel protein ClC-Ka inducer; Prostaglandin G/H synthase 1; Cytosolic phospholipase A2; UDP-glucuronosyltransferase 1-9 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |